Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence in the Mouse Model of Intraperitoneal Infection.


Journal

Infection and immunity
ISSN: 1098-5522
Titre abrégé: Infect Immun
Pays: United States
ID NLM: 0246127

Informations de publication

Date de publication:
11 2019
Historique:
received: 01 08 2019
accepted: 07 08 2019
pubmed: 14 8 2019
medline: 14 1 2020
entrez: 14 8 2019
Statut: epublish

Résumé

Porcine mucin has been commonly used to enhance the infectivity of bacterial pathogens, including

Identifiants

pubmed: 31405959
pii: IAI.00591-19
doi: 10.1128/IAI.00591-19
pmc: PMC6803341
pii:
doi:

Substances chimiques

Mucins 0
Recombinant Proteins 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Crown copyright 2019.

Références

Microbes Infect. 2009 Oct;11(12):946-55
pubmed: 19573619
J Antimicrob Chemother. 1985 Apr;15(4):441-8
pubmed: 4008377
Bacteriol Rev. 1948 Jun;12(2):149-72
pubmed: 16350119
J Antimicrob Chemother. 2012 Jun;67(6):1439-45
pubmed: 22389456
Infect Chemother. 2017 Mar;49(1):57-61
pubmed: 28271653
Infect Immun. 1980 Sep;29(3):886-91
pubmed: 6159328
Antimicrob Agents Chemother. 2013 Aug;57(8):3601-13
pubmed: 23689726
J Infect Dis. 2017 Feb 15;215(suppl_1):S52-S57
pubmed: 28375520
Medchemcomm. 2018 Jun 18;9(7):1206-1212
pubmed: 30109009
Infect Immun. 2019 Mar 25;87(4):
pubmed: 30745328
Vaccine. 2017 Mar 7;35(10):1440-1447
pubmed: 28190743
Infect Immun. 1979 May;24(2):545-51
pubmed: 110703
Infect Immun. 2009 Mar;77(3):1015-21
pubmed: 19103777
Clin Microbiol Rev. 2008 Jul;21(3):538-82
pubmed: 18625687
J Infect Dis. 2006 Jan 15;193(2):187-95
pubmed: 16362882
Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1391-8
pubmed: 21479973
Infect Immun. 2007 Dec;75(12):5597-608
pubmed: 17908807
Virulence. 2013 Aug 15;4(6):467-72
pubmed: 23863607
Int J Med Microbiol. 2014 May;304(3-4):360-9
pubmed: 24440358
Infect Immun. 2011 Aug;79(8):3317-27
pubmed: 21576323
Infect Immun. 1980 Feb;27(2):449-54
pubmed: 6155334
Cell Host Microbe. 2013 May 15;13(5):509-519
pubmed: 23684303
New Microbiol. 2015 Jan;38(1):67-73
pubmed: 25742149
Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8676-80
pubmed: 1528880
Br J Exp Pathol. 1952 Aug;33(4):327-39
pubmed: 14954104
PLoS One. 2018 Jan 8;13(1):e0190599
pubmed: 29309434
Infect Immun. 2011 Jan;79(1):518-26
pubmed: 20974823
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9599-604
pubmed: 27506797
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31209004
Vaccine. 2011 Aug 5;29(34):5705-10
pubmed: 21679737
Int Immunopharmacol. 2011 Sep;11(9):1378-83
pubmed: 21496497
Can J Microbiol. 1959 Feb;5(1):73-7
pubmed: 13629387
J Bacteriol. 1958 Dec;76(6):631-9
pubmed: 13610801
Front Immunol. 2017 Apr 12;8:441
pubmed: 28446911
Clin Microbiol Rev. 2017 Jan;30(1):409-447
pubmed: 27974412
J Clin Microbiol. 2008 Aug;46(8):2499-507
pubmed: 18524965
Curr Protoc Microbiol. 2017 Aug 11;46:6G.3.1-6G.3.23
pubmed: 28800159
FEMS Microbiol Rev. 2013 Mar;37(2):130-55
pubmed: 22568581
PLoS One. 2014 Jun 23;9(6):e100727
pubmed: 24956279
Can J Microbiol. 1976 Jun;22(6):832-8
pubmed: 819118
Clin Microbiol Infect. 2007 Feb;13(2):196-198
pubmed: 17328733
Int J Infect Dis. 2012 Jan;16(1):e34-40
pubmed: 22088863
Br J Exp Pathol. 1954 Dec;35(6):528-38
pubmed: 13230409
Biopolymers. 2011;96(2):126-9
pubmed: 20564029
Infect Immun. 2019 Mar 25;87(4):
pubmed: 30718286
Sci Rep. 2019 Apr 25;9(1):6538
pubmed: 31024025
Antimicrob Agents Chemother. 1997 Feb;41(2):345-51
pubmed: 9021190
Infect Immun. 2012 Oct;80(10):3381-8
pubmed: 22825448
J Infect Dis. 2015 Apr 15;211(8):1296-305
pubmed: 25378635
Infect Immun. 2017 Feb 23;85(3):
pubmed: 28052995
Antimicrob Agents Chemother. 2012 Oct;56(10):5397-400
pubmed: 22825117
Am J Respir Crit Care Med. 2006 Jan 1;173(1):122-9
pubmed: 16210672
PLoS One. 2012;7(6):e40019
pubmed: 22768201

Auteurs

Greg Harris (G)

Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, Ontario, Canada.

Bruce E Holbein (BE)

Chelation Partners Inc., Halifax, Nova Scotia, Canada.
Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.

Hongyan Zhou (H)

Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, Ontario, Canada.

H Howard Xu (HH)

Department of Biological Sciences, California State University, Los Angeles, Los Angeles, California, USA.

Wangxue Chen (W)

Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, Ontario, Canada Wangxue.Chen@nrc.gc.ca.
Department of Biology, Brock University, St. Catharines, Ontario, Canada.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH